Status:
COMPLETED
Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Susan G. Komen Breast Cancer Foundation
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-70 years
Brief Summary
The purpose of this study is to examine breast cancers that express the protein (NIS) that may be found in malignant breast tissues and to evaluate proteins found in blood and their relationship to NI...
Detailed Description
To demonstrate iodide uptake capacity of breast cancer metastases by imaging women with iodide radioisotope (123I) and calculating potential ablative dose of radioactive iodide (131I).
Eligibility Criteria
Inclusion
- Only women diagnosed with breast cancer
- 18 years of age or older
- From whom informed consent can be obtained
- Patient is able to provide a fluid (e.g. cyst fluid)
- Patient with blood test that shows protein may allow iodide to accumulate in breast tissue
- Patient who's breast cancer cells accumulated I123 and held on to it for 24 hours
Exclusion
- Males
- Children
Key Trial Info
Start Date :
November 1 2000
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2008
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00185809
Start Date
November 1 2000
End Date
August 1 2008
Last Update
July 20 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305